News | Patient Positioning Radiation Therapy | July 19, 2019

Stronger Distribution Networks to Bolster Radiotherapy Patient Positioning Accessories

Global revenues for radiotherapy patient positioning devices to exceed $500 million in 2019

Stronger Distribution Networks to Bolster Radiotherapy Patient Positioning Accessories

July 17, 2019 — A recent study projects global market revenues for radiotherapy patient positioning accessories will exceed revenues of $500 million in 2019. This represents a moderate 4.3 percent annual growth over 2018, with nearly 1/5 of the overall installed base of radiotherapy patient positioning accessories accounted for by couch tops and overlays, followed by immobilization systems.

More than 40 percent of the total adoption of radiotherapy patient positioning accessories is registered by hospitals at a global level, as indicated by the report from Future Market Insights. A higher rate of demand for radiotherapy patient positioning accessories is likely to be recorded by cancer research institutes and radiation therapy/proton therapy centers in the forthcoming years.

Government Support Pivotal in Accelerating Installation of Radiotherapy Patient Positioning Accessories

North America and Europe currently hold a combined revenue share of more than 60 percent in the global radiotherapy patient positioning accessories market. A remarkable increase in the rate of early cancer diagnosis is leading to a hike in the adoption of radiotherapy, more prominently in developed countries such as the U.S., U.K. and Germany among others, according to the FMI report. Moreover, the study opines that the increasing awareness about multiple types of cancers, further backed by favorable government initiatives regarding cancer diagnosis and treatment, will be one of the strongest factors pushing penetration of radiotherapy patient positioning accessories within developed regional markets.

On the other side, governments of several developing economies are also extending support and investments in the cancer diagnosis and treatment space, particularly through screening camps, which is boosting the diagnosis rates of cancer. This according to the report is majorly responsible for promising growth in the installed base of radiotherapy systems and patient positioning accessories. According to analysis, the flourishing medical tourism sector is also registering significant contribution to the thriving demand for radiotherapy patient positioning accessories in emerging economies.

Strategic Efforts in Stronger Distribution Network Gathering Momentum Among Manufacturers

Some of the key players actively competing in the radiotherapy patient positioning accessories market include Bionix Radiation Therapy, CDR Systems, Civco Radiation, Orfit Industries N.V., IZI Medical Products, Klarity Medical Products, Qfix, Elekta AB, and Eckert & Ziegler BEBIG, among others. Several leading manufacturers are focused on the development and approval of new products. For example, Civco Radiotherapy announced U.S. Food and Drug Administration (FDA) clearance and CE mark for their Solstice SRS (stereotactic radiosurgery) Immobilization System, in the second half of 2018.

Strong distribution partnerships tend to result in effective product reach across the value chain and thereby support the business growth. While the growing trend of strategic distribution partnerships between peer companies operating in the radiotherapy patient positioning accessories market is translating into improved product outreach, the analysis suggests that collaborative activities will particularly benefit smaller players in the market. Recently, Poll Medical entered a partnership with Civco for the global distribution of Poll’s CE-marked GrayDuck Stents, a new custom oral stent to provide immobilization and tissue sparing of the tongue during head and neck radiotherapy. 

Access the full FMI report here.

For more information: www.futuremarketinsights.com

Related Content

An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.
News | Clinical Trials | February 03, 2020
February 3, 2020 — Melding the genetic and cellular analysis of tumors with how they appear in medical images could g